KT109
Code | Size | Price |
---|
TAR-T27752-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T27752-50mg | 50mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
KT109 is a selective inhibitor of DAGLβ (IC50 = 42 nM). KT109-treated wild-type mice displayed reductions in LPS-induced allodyni as well as in DAGL-β (-/-) micea. Repeated KT109 administration prevented the expression of LPS-induced allodynia, without evidence of tolerance. Intraplantar injection of KT109 into the LPS-treated paw, but not the contralateral paw, reversed the allodynic responses. KT109 also reversed allodynia in the CCI and CINP models and lacked discernible side effects (e.g. anxiogenic behaviour, gross motor deficits or gastric ulcers).
CAS:
1402612-55-8
Formula:
C27H26N4O
Molecular Weight:
422.532
Purity:
0.98
SMILES:
O=C(N1CCCCC1Cc1ccccc1)n1cc(nn1)-c1ccc(cc1)-c1ccccc1
References
1. Wilkerson JL, Ghosh S, Bagdas D, Mason BL, Crowe MS, Hsu KL, Wise LE, Kinsey SG, Damaj MI, Cravatt BF, Lichtman AH. Diacylglycerol lipase ? inhibition reverses nociceptive behaviour in mouse models of inflammatory and neuropathic pain. Br J Pharmacol. 2016 May;173(10):1678-92. doi: 10.1111/bph.13469. PubMed PMID: 26915789; PubMed Central PMCID: PMC4842918.